Display options
Cite
Dou Z, Lin S, Dai C, et al. Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget. 2017;8(37):62703-62715doi: 10.18632/oncotarget.18697.
Dou, Z., Lin, S., Dai, C., Lu, Y., Tian, T., Wang, M., Liu, X., Zheng, Y., Xu, P., Li, S., Sheng, Q., Deng, Y., & Dai, Z. (2017). Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget, 8(37), 62703-62715. https://doi.org/10.18632/oncotarget.18697
Dou, Zhe, et al. "Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers." Oncotarget vol. 8,37 (2017): 62703-62715. doi: https://doi.org/10.18632/oncotarget.18697
Dou Z, Lin S, Dai C, Lu Y, Tian T, Wang M, Liu X, Zheng Y, Xu P, Li S, Sheng Q, Deng Y, Dai Z. Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget. 2017 Jun 27;8(37):62703-62715. doi: 10.18632/oncotarget.18697. eCollection 2017 Sep 22. PMID: 28977982; PMCID: PMC5617542.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 27;8(37):62703-62715. doi: 10.18632/oncotarget.18697. eCollection 2017 Sep 22.

Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers.

Oncotarget

Zhe Dou, Shuai Lin, Cong Dai, Ye Lu, Tian Tian, Meng Wang, Xinghan Liu, Yi Zheng, Peng Xu, Shanli Li, Qianwen Sheng, Yujiao Deng, Zhijun Dai

Affiliations

  1. Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
  2. Department of Student Affairs, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.

PMID: 28977982 PMCID: PMC5617542 DOI: 10.18632/oncotarget.18697

Abstract

Many studies manifested miRNA-100 was deregulated in various cancers, which indicated that miRNA-100 might be a potential biomarker of cancer diagnosis and prognosis. However, the role of miRNA-100 was still uncertain. We searched for qualified studies using PubMed, EMBASE, Web of Science, Cochrane library and CNKI databases. The diagnostic effect was evaluated by the pooled sensitivity, specificity, and other indexes. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were calculated to assess the prognostic value. This meta-analysis included 7 and 19 studies about diagnosis and prognosis, respectively. The results of pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) were 0.75 (95%CI: 0.71-0.78), 0.74 (95%CI: 0.69-0.78), 2.61 (95%CI: 1.81-3.76), 0.33 (95%CI: 0.24-0.45), 8.46 (95%CI: 4.85-14.77), respectively. And, the area under SROC curve (AUC) was 0.8141. We also found that lower expression of miRNA-100 in cancer tissues could significantly predict poorer prognosis in overall cancer (HR = 0.59, 95%CI: 0.39-0.90), especially in genital system tumors (HR = 0.42, 95%CI: 0.27-0.66, P = 0.431), bladder cancer (HR = 0.21, 95%CI: 0.06-0.73, P = 0.143) and esophageal squamous cell carcinoma (HR = 0.26, 95%CI: 0.13-0.52, P = 0.164). Our studies concluded that miRNA-100 has a certain value in diagnosis and it may indicate a poor prognosis of cancers.

Keywords: diagnosis; meta-analysis; miRNA-100; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Eur J Cancer. 2014 May;50(8):1541-54 - PubMed
  2. Tumour Biol. 2015 Aug 28;:null - PubMed
  3. Int J Physiol Pathophysiol Pharmacol. 2011;3(2):140-55 - PubMed
  4. Asian Pac J Cancer Prev. 2014;15(24):10943-7 - PubMed
  5. Tumour Biol. 2016 Aug;37(8):10571-6 - PubMed
  6. Cell Biochem Funct. 2016 Apr;34(3):142-8 - PubMed
  7. Zhonghua Zhong Liu Za Zhi. 2015 Aug;37(8):603-8 - PubMed
  8. BMC Cancer. 2012 Aug 24;12 :369 - PubMed
  9. Clin Chem. 2010 Dec;56(12):1871-9 - PubMed
  10. Mol Oncol. 2012 Dec;6(6):590-610 - PubMed
  11. PLoS One. 2012;7(3):e33762 - PubMed
  12. PLoS One. 2014 Mar 20;9(3):e92292 - PubMed
  13. Oncogene. 2017 Feb 23;36(8):1023-1037 - PubMed
  14. J Mol Diagn. 2013 Sep;15(5):695-705 - PubMed
  15. Oncotarget. 2016 Feb 2;7(5):5702-14 - PubMed
  16. Asian Pac J Cancer Prev. 2011;12(11):3001-4 - PubMed
  17. Diagn Pathol. 2012 Nov 22;7:159 - PubMed
  18. Mol Med Rep. 2016 Jun;13(6):4549-60 - PubMed
  19. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  20. EMBO Mol Med. 2012 Mar;4(3):143-59 - PubMed
  21. Expert Rev Mol Diagn. 2010 Apr;10(3):297-308 - PubMed
  22. Cancer Lett. 2012 Apr 28;317(2):184-91 - PubMed
  23. J Surg Res. 2014 Dec;192(2):515-20 - PubMed
  24. Onco Targets Ther. 2012;5:213-9 - PubMed
  25. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  26. Mol Cell Biochem. 2013 Nov;383(1-2):49-58 - PubMed
  27. J Urol. 2012 Nov;188(5):1951-6 - PubMed
  28. J Evid Based Med. 2015 Feb;8(1):2-10 - PubMed
  29. PLoS One. 2012;7(8):e43268 - PubMed
  30. J Hepatol. 2010 Apr;52(4):550-9 - PubMed
  31. World J Gastroenterol. 2014 Jan 7;20(1):142-7 - PubMed
  32. Med Oncol. 2014 Dec;31(12):298 - PubMed
  33. Mol Cancer Ther. 2013 Feb;12(2):207-19 - PubMed
  34. Am J Transl Res. 2016 May 15;8(5):2403-10 - PubMed
  35. BMC Med Res Methodol. 2006 Jul 12;6:31 - PubMed
  36. Tumour Biol. 2014 Apr;35(4):3067-71 - PubMed
  37. Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H931-9 - PubMed
  38. Sci Rep. 2015 Jul 01;5:11650 - PubMed
  39. Med Oncol. 2014 Oct;31(10):235 - PubMed
  40. Br J Cancer. 2013 Oct 15;109(8):2189-98 - PubMed
  41. PLoS One. 2009 Nov 13;4(11):e7826 - PubMed
  42. Oncol Rep. 2012 Apr;27(4):1238-44 - PubMed
  43. BMC Cancer. 2012 Nov 14;12:519 - PubMed
  44. Cell Signal. 2015 Jun;27(6):1087-101 - PubMed
  45. Int Urol Nephrol. 2013 Apr;45(2):373-9 - PubMed
  46. Med Oncol. 2013 Mar;30(1):411 - PubMed
  47. Genet Mol Res. 2015 Dec 07;14(4):15948-54 - PubMed
  48. Clin Epigenetics. 2015 Dec 23;7:132 - PubMed

Publication Types